Add BrightSurf on Google Email

Cardiac MRI may lead to targeted PAH therapy

05.20.19 | American Thoracic Society
Apple iPhone 17 Pro

Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Pulmonary Arterial Hypertension
Patients at greatest risk of dying from pulmonary arterial hypertension (PAH) may be identified through cardiac magnetic resonance imaging (MRI) and the information the noninvasive scan provides about the functional level of the heart's right ventricle Credit: ATS

ATS 2019, Dallas, TX -- Patients at greatest risk of dying from pulmonary arterial hypertension (PAH) may be identified through cardiac magnetic resonance imaging (MRI) and the information the noninvasive scan provides about the functional level of the heart's right ventricle, according to research presented at ATS 2019. Researchers said stratification of mortality risk in PAH can help doctors provide targeted therapies to those at greatest risk and measure their effectiveness by monitoring right ventricular function.

###

VIEW ABSTRACT

Session: B27 Heartbreaker: Heart Failure and Pulmonary Hypertension
Abstract Presentation Time: Monday, May 20, 9:15 a.m. CT
Location: Room C141/C143/C149 (Level 1), Kay Bailey Hutchison Convention Center Dallas

Keywords

Heart Ventricles Magnetic Resonance Imaging Pulmonary Hypertension

Contact Information

Dacia Morris
Dmorris@thoracic.org

How to Cite This Article

APA:
American Thoracic Society. (2019, May 20). Cardiac MRI may lead to targeted PAH therapy. Brightsurf News. https://www.brightsurf.com/news/LQMOK4X1/cardiac-mri-may-lead-to-targeted-pah-therapy.html
MLA:
"Cardiac MRI may lead to targeted PAH therapy." Brightsurf News, May. 20 2019, https://www.brightsurf.com/news/LQMOK4X1/cardiac-mri-may-lead-to-targeted-pah-therapy.html.